- Home
- DEA vs FTRE Comparison
DEA vs FTRE Comparison
Compare DEA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- FTRE
- Stock Information
- Founded
- DEA 2011
- FTRE 1996
- Country
- DEA United States
- FTRE United States
- Employees
- DEA N/A
- FTRE N/A
- Industry
- DEA Real Estate Investment Trusts
- FTRE Medical Specialities
- Sector
- DEA Real Estate
- FTRE Health Care
- Exchange
- DEA Nasdaq
- FTRE Nasdaq
- Market Cap
- DEA 998.2M
- FTRE 864.4M
- IPO Year
- DEA 2015
- FTRE N/A
- Fundamental
- Price
- DEA $21.96
- FTRE $9.45
- Analyst Decision
- DEA Buy
- FTRE Hold
- Analyst Count
- DEA 6
- FTRE 9
- Target Price
- DEA $26.41
- FTRE $13.06
- AVG Volume (30 Days)
- DEA 487.1K
- FTRE 1.2M
- Earning Date
- DEA 10-27-2025
- FTRE 11-05-2025
- Dividend Yield
- DEA 8.19%
- FTRE N/A
- EPS Growth
- DEA N/A
- FTRE N/A
- EPS
- DEA 0.38
- FTRE N/A
- Revenue
- DEA $322,861,000.00
- FTRE $2,733,500,000.00
- Revenue This Year
- DEA $9.33
- FTRE N/A
- Revenue Next Year
- DEA $6.93
- FTRE N/A
- P/E Ratio
- DEA $58.19
- FTRE N/A
- Revenue Growth
- DEA 7.93
- FTRE N/A
- 52 Week Low
- DEA $19.33
- FTRE $3.97
- 52 Week High
- DEA $36.31
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- DEA 44.78
- FTRE 49.20
- Support Level
- DEA $21.77
- FTRE $9.21
- Resistance Level
- DEA $22.70
- FTRE $10.05
- Average True Range (ATR)
- DEA 0.49
- FTRE 0.63
- MACD
- DEA -0.03
- FTRE -0.08
- Stochastic Oscillator
- DEA 52.09
- FTRE 40.51
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.